Pliant Therapeutics Stock News

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.30% and 12.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.30% and 12.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis The FDA's Psychopharmaco

Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need. Roche Holdings AG's (OTC: RHHBY) Esbriet and 

Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need. Roche Holdings AG's (OTC: RHHBY) Esbriet and 

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, February 28th by Pliant Therapeutics, Inc. (Nasdaq: PLRX), please note that in the Condensed Statements of Operations table, the Year Ended 2021 value was missing from the Research and development line and the corresponding totals were understated by the omitted value. The corrected release follows:

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 10.53% and 45.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Pliant Therapeutics press release (NASDAQ:PLRX): Q4 GAAP EPS of -$0.68 beats by $0.09.Revenue of $2M (-55.2% Y/Y) misses by $0.14M.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter and full year 2021 financial results.

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 10.53% and 45.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

At all dose levels, PLN-74809 demonstrated durable pSmad suppression relative to placebo at 6 hours and 24 hours TGF-β suppression of up to 92% and 76% from baseline at 6 and 24 hours, respectively PLN-74809 was well tolerated with no serious or severe adverse events SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ: PLRX ) today announced positive data from its expanded PLN-74809 Phase 1b proof-of-mechanism trial. PLN-74809 demonstrated clear evidence of on-target biological activity in the lungs of healthy participants. Results showed that PLN-74809 inhibited TGF-β activation on Day 7 by up to 92% and 76% at 6- and 24-hours, respectively, following dosing. TGF-β has been shown to be a key mediator of the fibrosis pathway in idiopathic pulmonary fibrosis (IPF). "Today''s data expand upon previous results providing evidence of PLN-74809''s ability to inhibit activation of TGF-β, a key molecular driver of fibrosis, in the lungs of healthy volunteers.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly''s Co-developed Diabetes Drug Jardiance Gets Label Expansion To Treat Hear Failure Lilly & Company, Inc. (NYSE: LLY ) announced the U.S. Food and Drug Administration has approved Jardiance, 10 mg, to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. Lilly is co-developing the drug with Boehringer Ingelheim. Pliant Commences Mid-stage Study of Idiopathic Pulmonary Fibrosis Treatment Following Positive Independent Safety Review Pliant Therapeutics, Inc. (NASDAQ: PLRX ) said, following a positive independent Data Safety Monitoring Board safety review, it has begun rolling in a Phase 2a trial of PLN-74809 at 320 mg dosed once daily for at least six months in patients with idiopathic pulmonary fibrosis. The stock was up 2.02% at $8.59 in premarket trading. Aquestive Announces FDA Clearance For Study Of Allergy Treatment Candidate AQST-109 Aquestive Therapeutics, Inc. (NASDAQ: AQST ) announced the clearance of its investigational new Drug Application from the FDA for its drug candidate AQST-109 epinephrine oral film for the emergency treatment of severe allergic reactions, including anaphylaxis.

Pliant Therapeutics (PLRX) said that following a positive independent safety review, enrollment has begun in a phase 2a trial of PLN-74809 at 320 mg dose in patients with…

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at 320mg